Is there a UK (or UK-registered) patent for fidaxomicin, and who holds it?
The information needed to answer this depends on which “UK patent information” you want (a UK patent document, a UK part of a European patent that was validated in the UK, or a UK-listed regulatory exclusivity/patent linkage entry). The provided material does not include any patent numbers, assignees, application/publication dates, or links to UK patent registers, so I can’t identify specific UK patents or owners for fidaxomicin from it.
To pull the right UK record, you’d typically search the UK Intellectual Property Office (UKIPO) and/or EPO Espacenet using:
- “fidaxomicin” and synonyms
- the marketing authorisation holder/brand name (if known)
- applicant/assignee names (if known)
- family members (EP/PCT filings) that entered the UK
If you share either (1) a patent number or application number you’ve already found, or (2) the marketing authorisation holder name, I can help you interpret it (scope, priority, term, and whether it’s likely to cover the drug product or a process).
How do you find fidaxomicin patent filings in the UK (UKIPO vs Espacenet)?
For “UK patent information,” there are two common routes:
1) Search UKIPO directly for UK patent publications and grants using “fidaxomicin” in the title/abstract/claims.
2) Use Espacenet to find the patent family for fidaxomicin, then check which family members were validated in the UK (UK designations).
These approaches matter because many drug patents are filed as EP/PCT first and then have a UK national phase/validation outcome, so the “UK” patent may appear as a translated publication (or as the EP family member with UK effects) rather than as a UK-only application.
What patents are most likely relevant to fidaxomicin (drug substance vs formulation vs method)?
When people ask for fidaxomicin UK patent information, they often want to know whether the relevant protection covers:
- the active ingredient (fidaxomicin or specific crystalline forms),
- a manufacturing process,
- a formulation (e.g., tablet composition, polymorph/formulation),
- or a method of treatment (e.g., treating CDI).
Those categories affect what “counts” for market barriers and how later entrants might design around the patent. Pinning this down requires the specific claims from the UK-affected patent documents.
How long would a UK fidaxomicin patent last (and what can extend it)?
Patent term in the UK usually starts from the priority date (standard 20-year term), with possible extensions depending on regulatory status and the patent type (e.g., supplementary protection mechanisms). Whether those extensions apply to fidaxomicin depends on the exact UK patent, its priority, and any associated regulatory protection.
To determine the actual end date for a specific UK fidaxomicin patent, you need:
- the priority date,
- the UK publication/grant number,
- and any extension/validation details shown on the UK patent register entry.
Can biosimilars/generics enter the UK before fidaxomicin patents expire?
The ability of generics to enter depends on whether there is any active patent (or other regulatory exclusivity) that prevents supply and whether the generic can be launched without infringing.
- If patents covering fidaxomicin substance/formulation/method are still in force, launch timing is constrained.
- If patents are expired or can be designed around (e.g., different form/process not covered by claims), entry may be possible earlier.
Again, this can’t be mapped without the specific UK patent documents you care about.
If you want, I can extract exact UK patent details—what do you need to provide?
Send one of the following and I’ll produce a clean “UK patent information” readout (document numbers, priority/filing dates, likely claim scope, and likely relevance to product supply):
- A UK patent number/publication number you’ve found, or
- A link to a UKIPO/Espacenet page you’re looking at, or
- The marketing authorisation holder/brand name for fidaxomicin in the UK, plus any known strength/form (e.g., tablet strength).
Sources
No sources were provided in the prompt, so I can’t cite UK fidaxomicin patent records yet.